(HealthDay News) — Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ...
(HealthDay News) — Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures, ...
The approval was based on data from the BLUE-C trial, which assessed the sensitivity and specificity of the Cologuard Plus test vs FIT in asymptomatic adults scheduled for screening colonoscopy.